Print

MediciNova, Inc. Meets With FDA for End-of-Phase 2 Meeting for MN-221 for the Treatment of Acute Exacerbations of Asthma  
10/23/2012 9:06:51 AM

SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it conducted an End-of-Phase 2 meeting pertaining to the development of MN-221 for the treatment of acute exacerbations of asthma with the United States Food and Drug Administration (FDA) earlier today.